Skip to main content
SpringerLink
Log in

Hematologic Malignancies: Lymphoma, Leukemia, Multiple Myeloma

  • Chapter
PET-CT

  • 920 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-Fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38(6):799–804.

    Article  PubMed  Google Scholar 

  2. Delbeke D, Martin WH. Positron emission tomography in oncology. Radiol Clin North Am 2001;39:883–917.

    Article  PubMed  Google Scholar 

  3. Delbeke D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma, and melanoma. J Nucl Med 1999;40:591–603.

    Google Scholar 

  4. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-Ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465–474.

    PubMed  Google Scholar 

  5. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-Labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267–272.

    PubMed  Google Scholar 

  6. Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64(4):336–340.

    Article  PubMed  Google Scholar 

  7. Ilknur AK, et al. Positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose in oncology: Part II: The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000;126:560–574.

    PubMed  Google Scholar 

  8. Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002;31(12):690–694.

    Article  PubMed  Google Scholar 

  9. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002;43:1018–1027.

    PubMed  Google Scholar 

  10. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224–239.

    PubMed  Google Scholar 

  11. Lee J. Dichotomy between Tc-99m MDP bone scan and Fluorine-18 fluorodeoxyglucose coincidence detection positron emission tomography in patients with non-Hodgkin’s lymphoma. Clin Nucl Med 2000;25:532–535.

    Article  PubMed  Google Scholar 

  12. Tatsumi M, Kitayama H, Sugahara H, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin’s lymphoma. J Nucl Med 2001;42:601–608.

    PubMed  Google Scholar 

  13. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 2001;115:793–800.

    Article  PubMed  Google Scholar 

  14. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice HG, Mehta A. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117(1):133–135.

    Article  PubMed  Google Scholar 

  15. Rini JN, Leonidas JC, Tomas MB, et al. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003;44:1072–1074.

    PubMed  Google Scholar 

  16. Romer W, Schwaiger N. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging 1998;1(2):101–110.

    Article  PubMed  Google Scholar 

  17. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: Assesment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464–4471.

    PubMed  Google Scholar 

  18. Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision-making for malignant lymphoma. Ann Nucl Med 2002;16(5):337–345.

    PubMed  Google Scholar 

  19. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imag 2002;29(3):361–366.

    Article  Google Scholar 

  20. Schoder H, Meta J, Yap C, et al. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001;42:1139–1143.

    PubMed  Google Scholar 

  21. Shen YY, Wu Hs, Huang WS, et al. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002;9:321–325.

    PubMed  Google Scholar 

  22. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F] FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F] FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–419.

    PubMed  Google Scholar 

  23. Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using 18F-FDG PET. J Nucl Med 2002;43:1028–1030.

    PubMed  Google Scholar 

  24. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 2001;39(1–2):181–194.

    PubMed  Google Scholar 

  25. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Sem Nucl Med 2002;32(1):47–59.

    Google Scholar 

Download references

Authors
  1. Robert W. Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. PET Imaging Science Center, University of Southern California, Los Angeles, California, USA

    Peter S. Conti MD, PhD, FACNP, FACR (Professor of Radiology, Clinical Pharmacy & Biomedical Engineering, Director) & Daniel K. Cham MD, MS (Clinical Research Fellow) (Professor of Radiology, Clinical Pharmacy & Biomedical Engineering, Director) &  (Clinical Research Fellow)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Henderson, R.W. (2005). Hematologic Malignancies: Lymphoma, Leukemia, Multiple Myeloma. In: Conti, P.S., Cham, D.K. (eds) PET-CT. Springer, New York, NY. https://doi.org/10.1007/0-387-27044-2_18

Download citation

  • DOI: https://doi.org/10.1007/0-387-27044-2_18

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-20858-9

  • Online ISBN: 978-0-387-27044-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation